Nuveen’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-120,810
| Closed | -$223K | – | 3370 |
|
|
2023
Q1 | $223K | Sell |
120,810
-10,575
| -8% | -$13.1K | ﹤0.01% | 2969 |
|
|
2022
Q4 | $146K | Buy |
131,385
+15,431
| +13% | +$22K | ﹤0.01% | 3075 |
|
|
2022
Q3 | $272K | Sell |
115,954
-41,725
| -26% | -$148K | ﹤0.01% | 3066 |
|
|
2022
Q2 | $478K | Sell |
157,679
-1,591
| -1% | -$7.74K | ﹤0.01% | 3028 |
|
|
2022
Q1 | $1.02M | Sell |
159,270
-3,767
| -2% | -$26.9K | ﹤0.01% | 2813 |
|
|
2021
Q4 | $1.14M | Sell |
163,037
-4,023
| -2% | -$33.1K | ﹤0.01% | 2817 |
|
|
2021
Q3 | $1.3M | Buy |
167,060
+11,299
| +7% | +$70K | ﹤0.01% | 2875 |
|
|
2021
Q2 | $1.06M | Buy |
155,761
+29,838
| +24% | +$248K | ﹤0.01% | 2985 |
|
|
2021
Q1 | $1.29M | Buy |
125,923
+1,290
| +1% | +$14.1K | ﹤0.01% | 2804 |
|
|
2020
Q4 | $872K | Buy |
124,633
+54,598
| +78% | +$425K | ﹤0.01% | 2850 |
|
|
2020
Q3 | $571K | Buy |
70,035
+36
| +0.1% | +$223 | ﹤0.01% | 2907 |
|
|
2020
Q2 | $483K | Buy |
69,999
+1,963
| +3% | +$10.6K | ﹤0.01% | 2911 |
|
|
2020
Q1 | $323K | Buy |
68,036
+9,961
| +17% | +$57.3K | ﹤0.01% | 2913 |
|
|
2019
Q4 | $507K | Sell |
58,075
-24,763
| -30% | -$134K | ﹤0.01% | 2904 |
|
|
2019
Q3 | $276K | Sell |
82,838
-57,279
| -41% | -$229K | ﹤0.01% | 3060 |
|
|
2019
Q2 | $693K | Buy |
+140,117
| New | +$744K | ﹤0.01% | 2888 |
|
Other funds holding JNCE
Nuveen's JNCE Position: Q2 2023 in Review
Nuveen sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 120,810 shares — an estimated $223K sold.
Nuveen first reported a position in JNCE in Q2 2019 and held it in 16 quarters. The position peaked at $1.3M in Q3 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Nuveen reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Nuveen sold 120,810 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $223K.
- Nuveen first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- Nuveen's Jounce Therapeutics, Inc. Common Stock position peaked at $1.3M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Nuveen's 13F filing for Q2 2023, filed 14 Aug 2023.